Boulassel MR - Search Results

1

Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected persons.

Boulassel MR, Morales R, Murphy T, Lalonde RG, Klein MB. Boulassel MR, et al. J Med Virol. 2006 Sep;78(9):1158-63. doi: 10.1002/jmv.20676. J Med Virol. 2006. PMID: 16847953 Clinical Trial.

2

Interleukin-7 levels may predict virological response in advanced HIV-1-infected patients receiving lopinavir/ritonavir-based therapy.

Boulassel MR, Smith GH, Gilmore N, Klein M, Murphy T, MacLeod J, LeBlanc R, Allan J, René P, Lalonde RG, Routy JP. Boulassel MR, et al. HIV Med. 2003 Oct;4(4):315-20. doi: 10.1046/j.1468-1293.2003.00165.x. HIV Med. 2003. PMID: 14525542 Free article. Clinical Trial.

3

Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients.

Smith GH, Boulassel MR, Klien M, Gilmore N, MacLeod J, LeBlanc R, René P, Routy JP, Lalonde RG. Smith GH, et al. Among authors: boulassel mr. HIV Clin Trials. 2005 Mar-Apr;6(2):63-72. doi: 10.1310/HAG3-8YA5-UDQC-36NX. HIV Clin Trials. 2005. PMID: 15983890 Clinical Trial.

4

Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57.

Kamya P, Boulet S, Tsoukas CM, Routy JP, Thomas R, Côté P, Boulassel MR, Baril JG, Kovacs C, Migueles SA, Connors M, Suscovich TJ, Brander C, Tremblay CL, Bernard N; Canadian Cohort of HIV Infected Slow Progressors. Kamya P, et al. Among authors: boulassel mr. J Virol. 2011 Jun;85(12):5949-60. doi: 10.1128/JVI.02652-10. Epub 2011 Apr 6. J Virol. 2011. PMID: 21471235 Free PMC article.

5

Influence of RANTES, SDF-1 and TGF-beta levels on the value of interleukin-7 as a predictor of virological response in HIV-1-infected patients receiving double boosted protease inhibitor-based therapy.

Boulassel MR, Smith GH, Edwardes MD, Young M, Klein M, Gilmore N, Macleod J, Leblanc R, René P, Allan J, Lalonde RG, Routy JP. Boulassel MR, et al. HIV Med. 2005 Jul;6(4):268-77. doi: 10.1111/j.1468-1293.2005.00306.x. HIV Med. 2005. PMID: 16011532 Free article.

6

Changes in immunological and virological parameters in HIV-1 infected subjects following leukapheresis.

Boulassel MR, Spurll G, Rouleau D, Tremblay C, Edwardes M, Sekaly RP, Lalonde R, Routy JP. Boulassel MR, et al. J Clin Apher. 2003;18(2):55-60. doi: 10.1002/jca.10051. J Clin Apher. 2003. PMID: 12874816

7

Effects of drug resistance on viral load in patients failing antiretroviral therapy.

Machouf N, Thomas R, Nguyen VK, Trottier B, Boulassel MR, Wainberg MA, Routy JP. Machouf N, et al. Among authors: boulassel mr. J Med Virol. 2006 May;78(5):608-13. doi: 10.1002/jmv.20582. J Med Virol. 2006. PMID: 16555280

8

Assessing risk of a short-term antiretroviral therapy discontinuation as a read-out of viral control in immune-based therapy.

Routy JP, Boulassel MR, Nicolette CA, Jacobson JM. Routy JP, et al. Among authors: boulassel mr. J Med Virol. 2012 Jun;84(6):885-9. doi: 10.1002/jmv.23297. J Med Virol. 2012. PMID: 22499010 Clinical Trial.

9

Predictive value of interleukin-7 levels for virological response to treatment in HIV-1-infected children.

Boulassel MR, Samson J, Khammy A, Lapointe N, Soudeyns H, Routy JP. Boulassel MR, et al. Viral Immunol. 2007 Dec;20(4):649-56. doi: 10.1089/vim.2007.0047. Viral Immunol. 2007. PMID: 18158737

10

CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy.

Boulassel MR, Chomont N, Pai NP, Gilmore N, Sékaly RP, Routy JP. Boulassel MR, et al. J Clin Virol. 2012 Jan;53(1):29-32. doi: 10.1016/j.jcv.2011.09.018. Epub 2011 Oct 22. J Clin Virol. 2012. PMID: 22019250

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

93 results

Search Page